Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down‐regulation of oestrogen receptor‐α36
Open Access
- 1 June 2010
- journal article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 14 (6b) , 1485-1493
- https://doi.org/10.1111/j.1582-4934.2009.00877.x
Abstract
The dietary isothiocyanates (ITCs) exhibit strong chemopreventive activities for a variety of neoplasms including breast cancer. However, the molecular mechanisms underlying ITC function in breast cancer cells have not been well established. Here, we found that phenethyl isothiocyanate (PEITC) acted more potently than the ‘pure’ anti-oestrogen ICI 182,780 to inhibit the growth of oestrogen receptor (ER)+ breast cancer MCF7 and H3396 cells and ER– MDA-MB-231 and SK-BR-3 cells. PEITC reduced the steady state levels of ER-α and its novel variant, ER-α36 in a dose-and time-dependent manner and inhibited oestrogen-induced activation of the mitogen activated protein kinase/ERK 1/2 signaling pathway. However, ICI 182,780 that is potent in destabilization of ER-α protein, failed to down-regulate ER-α36. Our results thus demonstrated that PEITC functions as a more potent ER-α‘disruptor’ than the well-known ICI 182,780 to abrogate ER-mediated mitogenic oestrogen signaling in breast cancer cells, which provides a molecular explanation for the strong growth inhibitory activity of ITCs in breast cancer cells, and a rational for further exploration of ITCs as chemopreventive agents for human mammary carcinogenesis.Keywords
This publication has 35 references indexed in Scilit:
- Estrogen receptor‐alpha (ER‐α) suppresses expression of its variant ER‐α36FEBS Letters, 2009
- Benzyl isothiocyanate–induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and BakMolecular Cancer Therapeutics, 2006
- Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)Annals of Oncology, 2006
- A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signalingProceedings of the National Academy of Sciences, 2006
- Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanateCarcinogenesis: Integrative Cancer Research, 2006
- Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centreEndocrine-Related Cancer, 2006
- Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66Biochemical and Biophysical Research Communications, 2005
- Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cellsCarcinogenesis: Integrative Cancer Research, 2004
- Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen‐Sensitive and‐Resistant Experimental and Clinical Breast CanceraAnnals of the New York Academy of Sciences, 1995
- Fruit, vegetables, and cancer prevention: A review of the epidemiological evidenceNutrition and Cancer, 1992